Synonym
CGP-78608 hydrochloride, CGP-78608-HCl, CGP 78608 HCl, CGP78608 HCl, CGP-78608 HCl
IUPAC/Chemical Name
[(1S)-1-[[(7-Bromo-1,2,3,4-tetrahydro-2,3-dioxo-5-quinoxalinyl)methyl]amino]ethyl]phosphonic acid hydrochloride
InChi Key
MZQQZBPMRPDKTB-JEDNCBNOSA-N
InChi Code
InChI=1S/C11H13BrN3O5P.ClH/c1-5(21(18,19)20)13-4-6-2-7(12)3-8-9(6)15-11(17)10(16)14-8;/h2-3,5,13H,4H2,1H3,(H,14,16)(H,15,17)(H2,18,19,20);1H/t5-;/m0./s1
SMILES Code
C[C@H](P(O)(O)=O)NCC1=CC(Br)=CC(NC2=O)=C1NC2=O.[H]Cl
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
414.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Rouzbeh N, Rau AR, Benton AJ, Yi F, Anderson CM, Johns MR, Jensen L, Lotti JS, Holley DC, Hansen KB. Allosteric modulation of GluN1/GluN3 NMDA receptors by GluN1-selective competitive antagonists. J Gen Physiol. 2023 Jun 5;155(6):e202313340. doi: 10.1085/jgp.202313340. Epub 2023 Apr 20. PMID: 37078900; PMCID: PMC10125900.
2. Zeng Y, Zheng Y, Zhang T, Ye F, Zhan L, Kou Z, Zhu S, Gao Z. Identification of a Subtype-Selective Allosteric Inhibitor of GluN1/GluN3 NMDA Receptors. Front Pharmacol. 2022 Jun 9;13:888308. doi: 10.3389/fphar.2022.888308. PMID: 35754487; PMCID: PMC9218946.
3. Grand T, Abi Gerges S, David M, Diana MA, Paoletti P. Unmasking GluN1/GluN3A excitatory glycine NMDA receptors. Nat Commun. 2018 Nov 13;9(1):4769. doi: 10.1038/s41467-018-07236-4. PMID: 30425244; PMCID: PMC6233196.
4. Muth-Selbach U, Hermanns H, Stegmann JU, Kollosche K, Freynhagen R, Bauer I, Lipfert P. Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic system. Eur J Pharmacol. 2009 Jun 24;613(1-3):68-73. doi: 10.1016/j.ejphar.2009.04.043. Epub 2009 Apr 24. PMID: 19394327.
5. Gabra BH, Kessler FK, Ritter JK, Dewey WL, Smith FL. Decrease in N-methyl-D-aspartic acid receptor-NR2B subunit levels by intrathecal short-hairpin RNA blocks group I metabotropic glutamate receptor-mediated hyperalgesia. J Pharmacol Exp Ther. 2007 Jul;322(1):186-94. doi: 10.1124/jpet.107.120071. Epub 2007 Apr 3. PMID: 17405869.
6. Hilgier W, Oja SS, Saransaari P, Albrecht J. A novel glycine site-specific N-methyl-D-aspartate receptor antagonist prevents activation of the NMDA/NO/CGMP pathway by ammonia. Brain Res. 2004 Jul 23;1015(1-2):186-8. doi: 10.1016/j.brainres.2004.05.014. PMID: 15223384.
